Organization
3D Medicines
10 clinical trials
Clinical trial
Envafolimab(KN035) in Combination With Lenvatinib in the Treatment of Advanced Solid Tumors: a Multicenter, Open-label, Phase Ib/II StudyStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
Study of KN035 as Monotherapy in Patients With Advanced Mismatched Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Randomized, Double-blind, Single-dose, Parallel Controlled Phase I Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Envafolimab in Healthy Male Subjects Before and After the Manufacturing Process ChangeStatus: Recruiting, Estimated PCD: 2023-11-23
Clinical trial
An Open, Single-arm, Multi-center Phase II Clinical Study of ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-08-30
Clinical trial
An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III StudyStatus: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer PainStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase I Study to Evaluate the Safety and Immunogenicity of 3D189 in Patients With Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract CancersStatus: Not yet recruiting, Estimated PCD: 2026-06-01